S.5265

Establishes a Chief Pharmaceutical Trade Negotiator to address unfair international trade practices affecting U.S. pharmaceutical innovation.

The USTRx Act aims to counter international trade practices by high-income countries that exploit U.S. pharmaceutical innovation. It establishes a Chief Pharmaceutical Trade Negotiator within the Office of the United States Trade Representative to enforce trade agreements and address unfair practices. The bill mandates an annual report on high-income countries' pharmaceutical trade practices and requires a response plan for any identified unfair practices. The Act emphasizes the importance of ensuring fair market access and compensation for U.S. pharmaceutical innovation.